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ABSTRACT: Increasing evidence points to mitochondrial dysfunction in I Control 
Parkinson's disease (PD) associated with complex I dysfunction, but the exact 
pathways which lead to cell death have not been resolved. 2D-gel electrophoresis 
profiles of isolated mitochondria from neuroblastoma cells treated with sub-
cytotoxic concentrations of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine 
( M P T P ) , a well-characterized complex I inhibitor, were assessed to identify 
associated targets. U p to 27 differentially expressed proteins were observed, of 
which 16 were identified using peptide mass fingerprinting. Changes in protein 
levels were validated by immunoprobing I D blots, confirming increases in heat 
shock cognate 71 kDa (Hsc70), 60 kDa heat shock protein (Hsp60), fumarase, glutamate oxaloacetate transaminase 2, A T P 
synthase subunit d, and voltage-dependent anion-channel 1 ( V D A C l ) . Immunoprobing of 2D blots revealed isoform changes in 
Hsc70, Hsp60, and V D A C l . Subcyto toxic concentrations of M P T P modulated a host of mitochondrial proteins including 
chaperones, metabolic enzymes, oxidative phosphorylation-related proteins, an inner mitochondrial protein (mitofilin), and an 
outer mitochondrial membrane protein ( V D A C l ) . Early changes in chaperones suggest a regulated link between complex 1 
inhibition and protein folding. V D A C l , a multifunctional protein, may have a key role in signaling between mitochondria and the 
rest of the cell prior to cell death. Our work provides new important information of relevance to P D . 
KEYWORDS: Parkinson's disease, mitochondrial dysfunction, M P T P , complex I inhibition, 2DE, mitochondrial proteome, 
differentially expressed 
• INTRODUCTION 
25 Parkinson's disease (PD) is the second most common neu-
26 rodegenerative condition affecting 1 to 2% of the world's 
27 population over the age of 60. It is a progressive neurological 
28 movement disorder characterized by the selective degeneration 
29 of dopaminergic neurons, mainly in the substantia nigra pars 
30 compacta, linked with formation of proteinaceous inclusions, 
31 commonly known as Lewy bodies. Current treatments, invol-
32 ving maintenance of dopamine levels, alleviate the symptoms but 
33 do not prevent neurodegeneration, due to the fact that the exact 
34 pathways involved in the disease have not been completely 
35 resolved. Several hypotheses have been proposed including 
36 mitochondrial dysfunction, protein degradation impairment, 
37 defects in calcium homeostasis, glutamate excitotoxicity, inflam-
38 mation, and oxidative stress. ' Whether these features are 
39 linked, how they lead to neurodegeneration, and which are 
40 primary and secondary effects still remain unsolved. 
41 Mitochondrial dysfunction has been observed in both idio-
42 pathic and genetic forms of P D . For example, complex I activity 
43 of the electron transport chain ( E T C ) was up to 30% lower in 
44 brain, muscle, and platelets from P D patients and coenzyme Q_ 
45 10, an essential cofactor in the E T C , was decreased in P D 
46 patients; both characteristics would lead to increased intracel-
47 hilar oxidative stress, proton gradient impairment, and reduced 
48 A T P production. Additionally, DJ-1, P I N K 1 , and the protease 
49 Htra2/Omi have all been linked to genetic forms of the disease 
and are all localized in mitochondria and/or linked to mitochon-
drial function. The neurotoxin l-methyl-4-phenyl-l,2,3,6-tet-
rahydropyridine ( M P T P ) was originally observed to reproduce 
Parkinson's like symptoms in heroin addicts ingesting a synthetic 
narcotic containing the toxic substance. It has since been 
shown that M P T P can be metabolized by monoamine-oxidase 
( M A O ) - B into a toxic product, l-methyl-4-phenylpyrimidium 
( M P P ), which primarily targets nigrostriatal dopaminergic 
neurons via the dopamine uptake system, leading to inhibition 
of complex I of the E T C ' and cell death. M P T P became of 
particular interest when it was found to reproduce symptomatic, 
pathological, and biochemical features of P D in animal models ' 
and is one of the most commonly used pharmacology-based 
model of P D , both in vivo and in vitro. 
Proteomic approaches of relevance to P D have only emerged 
in the past decade, mostly concentrating on total cell extracts 
from a variety of experimental models, models involving both 
genetic or pharmacologic approaches, in vivo and in vitro. 
These include the effects of M P T P or M P P on mice, using 2D-
gel electrophoresis (2DE) or shotgun approaches, ' and on 
human neuroblastoma cells using 2DE. Many of these studies 
have led to the creation of lists of differentially expressed proteins 
containing 10—100 identities that do not always agree depending 
on the model, the approach, and the part of animal brain studied, 
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74 and only a few protein changes have been validated in their 
75 respective experimental model (3 proteins by Zhao et al., 1 by 
76 Palacino et al., and 2 by Xun et al. ). 
77 Few studies have concentrated on the mitochondrial pro-
78 teome. Jin and colleagues isolated mitochondria from the 
79 substantia nigra of P D patients, and subjected them to a pepti-
80 domic shotgun process, leading to the identification a large 
81 number of differentially expressed proteins in P D brains com-
82 pared to age-matched controls and validated only the decrease in 
83 mortalin, confirming its potential role in mitochondrial dysfunc-
84 tion. More recently, Pennington and colleagues enriched 
85 mitochondria from two human SH-SY5Y cell lines overexpres-
86 sing either wild-type or a mutant a-synuclein, the latter shown to 
87 be linked to P D pathology. The levels of only 8 proteins changed 
88 in the overexpressed mutant model, while the levels of many 
89 proteins changed in the cell line overexpressing wild-type a-
90 synuclein, of which only 34% of identified proteins were known 
91 to be located in mitochondria, suggesting the presence of a 
92 substantial number of nonmitochondrial proteins in the mito-
93 chondria-enriched fraction. There have been very few attempts 
94 to study the effects of toxins of relevance to P D specifically on the 
95 mitochondrial proteome. A shotgun proteomic approach has 
96 been used to analyze proteomic changes in mitochondrial 
97 fractions from the subtantia nigra of mice treated with M P T P , 
98 identifying up to 110 differentially expressed proteins and 
99 validating the change in expression in DJ-1 in both the mouse 
100 model and in human substantia nigra from P D patients. Finally, 
101 Jin and colleagues have analyzed mitochondrial proteomes from 
102 dopaminergic M E S cells treated with cytotoxic concentrations of 
103 rotenone leading to 50% cell death as measured by M T T reduc-
104 tion and Trypan blue exclusion assays. A combination of 1D-
105 gel electrophoresis and liquid chromatography—tandem mass 
106 spectrometry ( L C — M S ) was used to assess the mitochondria-
107 enriched fractions. They identified many differentially expressed 
108 proteins (110 mitochondrial proteins), probably due to the high 
109 level of toxicity, and validated 5 of these changes using Western 
no blotting, being one of the biggest number of validated potential 
i n markers up to date. 
112 Although in vivo models allow the study of pathological, 
113 behavioral, and symptomatic reactions and are essential for 
114 curative treatment trials prior to human testing, they involve 
lis a study of a mixture of cells and the actual concentration of an 
116 agent reaching particular neurons is not known. O n the other 
117 hand, established cell lines are essentially composed of one clonal 
118 cell type and they provide a good model for understanding the 
119 particular molecular pathways involved in a nonmetabolized 
120 treatment in a particular type of cell. Since the exact pathways 
121 involved in cell death following complex I inhibition are still not 
122 fully resolved, the present study investigated the effects of M P T P 
123 on the mitochondrial proteome. As the mouse model has been 
124 widely used for M P T P cytotoxic studies ' allowing in vitro 
125 studies to be compared to in vivo studies, the mouse N2a 
126 neuroblastoma cell line was chosen in the present study. N2a 
127 neuroblastoma cell line is an adrenergic clone that shows 
128 neuronal morphology characterized by cell bodies with a large 
129 number of elongated processes. The cell line contains high 
130 levels of tyrosine hydroxylase and also low levels of dopamine, 
131 norepinephrine, serotonin, and M A O . Mouse N2a neuroblas-
132 toma differentiation has been well-characterized following serum 
133 withdrawal and dibutyryl cyclic A M P (dbcAMP) treatment.41'42 
134 N2a cells have been used in a wide range of studies including 
135 toxicological studies ' and in vitro models for neurodegenerative 
diseases such as Alzheimer's disease, Huntington's disease, and 136 
P D . ' T o identify the pathways occurring early in neurodegenera- 137 
tion and prior to death of N2a cells, it was important to use a 138 
subcytotoxic concentration of M P T P in our study. Mtochondria 139 
were enriched from N2a cells using differential centrifugation and the 140 
degree of purity of the fraction was extensively analyzed using a 141 
combination of enzyme assays (succinate dehydrogenase [SDH], 142 
lactate dehydrogenase [LDH] , and NADPH-cytochrome c reduc- 143 
tase as mitochondrial, cytoplasmic, and endoplasmic reticulum 144 
markers, respectively) and antibody probing of Western blots to 145 
measure the presence of specific marker proteins (cytochrome c, 146 
G A P D H , lamin, and L A M P 2 as mitochondrial, cytoplasmic, nuclear, 147 
and lysosomal markers, respectively). 148 
Numerous proteomic studies carried out in P D research using 149 
cell lines have been 2 D E based. ' ' ' ' By combining 2 D E 150 
with peptide mass fingerprinting, proteins whose expression 151 
levels are altered can be selectively identified. Moreover, different 152 
isoforms and post-translationally modified proteins can be more 153 
easily distinguished. A 2DE-based proteomic approach was thus 154 
chosen to investigate the proteome of isolated mitochondria and 155 
to identify proteins affected prior to cell death by mild concen- 156 
trations of M P T P . The chosen concentration of M P T P reduced 157 
A T P levels significantly but did not lead to cell death, according 158 
to other markers of toxicity; thus, the aim was to study both the 159 
effects of A T P depletion together with the additional conse- 160 
quences of complex I inhibition. Validation of protein changes 161 
was then carried using alternative approaches, namely, I D - and 162 
2D-immunoprobing Western blots. 163 
• EXPERIMENTAL SECTION m 
Cell Culture and Treatments 165 
Mouse N2a neuroblastoma cells ( ICN, U.K.) were maintained 166 
as a monolayer in growth medium containing Dulbeco's mod- 167 
ified Eagle's medium ( D M E M ) , 10% (v/v) fetal bovine serum, 168 
2 m M 2-L-glutamine, 100 units/mL penicillin and 100 units/mL 169 
streptomycin (Lonza, U .K . ) . Cells were incubated and main- 170 
tained at 60—85% confluence at 37 °C in a humidified atmo- 171 
sphere of 95% air/5% C 0 2 (v/v). For cell differentiation, cells 172 
were plated at a density of 20 000 cells/cm and allowed to 173 
recover for 24 h. The growth medium was then removed and 174 
replaced by a differentiating medium containing 0.3 m M 175 
dbcAMP (Sigma-Aldrich, U.K. ) , 2 m M 2-L-glutamine, 100 176 
units/mL penicillin and 100 units/mL streptomycin in D M E M . 177 
Following 16 h incubation, fresh differentiating medium was 178 
added with or without M P T P ( 0 - 2 m M ; Sigma-Aldrich, U.K.) 179 
for a period of 24—48 h. The morphology of cells was recorded 180 
using a camera ( O L Y M P U S DN100 Digital Net Camera, Nikon, ISI 
Japan) attached to an inverted light microscope ( O L Y M P U S 182 
Nikon Eclipse TS100, Japan) at 400 X magnification. 183 
3-(4,5-Dimethylthiazol-2-yl)-2/5-diphenyltetrazolium Bro- 184 
mide (MTT) Reduction Assay iss 
Cell viability was monitored by measuring cellular metabolic 186 
activity in 96-well plates as described by Mosmann. In brief, 187 
following differentiation and treatment of cells (100 flL volume), 188 
10 flL of filtered M T T (Sigma-Aldrich, U K ) solution (5 mg/mL) 189 
was added to each well for 1 h. The medium was then carefully 190 
removed and 100 flL of dimethyl sulphoxide was added to each well. 191 
Following gentle agitation, the absorbance was measured at 570 nm. 192 
Results were expressed as mean percentage control (untreated cells) 193 
cell ± standard error of the mean (SEM). 194 
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195 Trypan Blue Exclusion Assay 
196 Cell membrane integrity was measured as described previou-
197 s ly 4 2 using the Trypan blue exclusion assay. Cell viability was 
198 expressed as mean % viability ± S E M compared to controls 
199 (untreated cells). 
200 ATP Assay 
201 Cellular A T P was monitored using the Vialight HS kit 
202 according to manufacturer's guidelines (Lumitech Ltd., U .K. ) . 
203 Luminescence was read using FLUOStar O P T I M A ( B M G 
204 Labtech, U.K.) and results were expressed as a mean percentage 
205 A T P ± S E M compared to untreated controls. 
206 Mitochondrial Isolation 
207 A l l the steps were undertaken on ice. Following differentiation 
208 and treatment, cells were harvested and washed several times in 
209 1 mL of sterile phosphate buffer saline (PBS). The resultant 
210 pellet was resuspended in 500 fiL of extraction buffer (EB) 
211 containing 10 m M H E P E S , p H 7.5, 70 m M sucrose, 200 m M 
212 mannitol, 1 m M E G T A , 1% (v/v) protease inhibitor cocktail 
213 (Sigma-Aldrich, U K ) and 1% (v/v) phosphatase inhibitor cock-
214 tail 2 (Sigma-Aldrich, U.K. ) , transferred into a Dounce, All-Glass 
215 2 mL capacity Tissue Grinder (Apollo Scientific, U.K. ) , and 
216 homogenized sequentially by 10 passes with loose fitting and 
217 close fitting pestles accompanying the grinder. Differential 
218 centrifugation was then carried out following a modified protocol 
219 from Lai and Clark. The homogenate was centrifuged at lOOOg 
220 for 10 min followed by a further 5 min centrifugation of the 
221 resuspended pellet in EB. The resulting pellet was termed the 
222 "nuclear-enriched fraction". Supernatants were combined and 
223 centrifuged at 10 OOOg for 15 min and the subsequent pellet was 
224 further centrifuged at 10 OOOg for 10 min after resuspension in 
225 E B . The resulting pellet was termed the "mitochondria-enriched 
226 pellet". Supernatants were combined and termed the "cytoplas-
227 mic fraction". Fractions were either stored at —80 °C or 
228 resuspended in E B for further analysis of purity assessment. 
229 Protein Estimation 
230 Protein concentration was estimated using the Bio-P^ad pro-
231 tein assay kit (Bio-Pvad Laboratories Ltd., U.K.) based on the 
232 Bradford method, used in accordance with the manufacturer's 
233 instructions. 
234 Succinate Dehydrogenase (SDH) Assay 
235 S D H activity was used to assay the presence of mitochondria 
236 in various subcellular fractions. Glass test tubes containing 1% 
237 (w/v) iodonitrotetrazolium, 100 flL of S D H buffer (0.25 M 
238 sodium phosphate, 5 mg/mL BSA, p H 7.4), 150 fiL of distilled 
239 water and 50 fiL of sample were equilibrated in a 37 °C water 
240 bath, 100 flL of sodium succinate (100 m M ) was added, and 
241 tubes were incubated for 1.5 hat 37 °C. The reaction was stopped 
242 by the addition of 500 / iL of trichloroacetic acid (10% (w/v)). 
243 Ethylacetate (3 mL) was added to each tube and thoroughly 
244 mixed. The organic phase was transferred to a polyvinyl chloride 
245 96-well-plate and absorbance read at 490 nm. T o check for 
246 enrichment, the mean specific activity per microgram protein was 
247 normalized against the specific activity of the total extract (given 
248 a value of l ) and data were expressed as mean ± S E M . 
249 Lactate Dehydrogenase (LDH) Assay 
250 L D H activity was used as a cytoplasmic marker in each 
251 fraction. In a plastic cuvette, 50 fiL of sodium pyruvate 
252 (27 m M ) , 50 flL of cellular fraction and 850 fiL of PBS (8 g /L 
253 sodium chloride, 0.2 g / L potassium chloride, 1.15 g / L sodium 
dihydrogen orthophosphate, 0.2 g / L disodium hydrogen) were 254 
added. The reaction was initiated with 50 flL of N A D H (4 m M ) 255 
and absorbance was recorded every 15 s for 3 min using a spe- 256 
ctrophotometer at 340 nm. The mean specific activity per 257 
microgram of protein for each fraction was normalized against 258 
the specific activity of the total extract (given a value of l ) and 259 
data were expressed as mean ± S E M . 260 
NADPH-cytochrome c Reductase 261 
NADPH-cytochrome c reductase activity was used as a marker 262 
of endoplasmic reticulum in each fraction. Assay buffer ( l mL) 263 
containing 50 m M sodium phosphate, 0.1 m M E D T A , p H 7.7, 50 264 
flL of cytochrome c (25 mg/mL) and 50 fiL of fraction sample 265 
were mixed prior to the addition of 100 fiL of N A D P H (2 mg/ 266 
mL) . Absorbance was recorded every 15 s for 3 min at 550 nm. 267 
The mean specific activity per microgram protein for each 268 
fraction was normalized against the specific activity of the total 269 
extract (given a value of l ) and data were expressed as mean 270 
± S E M . 271 
Western Blot Analysis 272 
This procedure was used for (a) analysis of marker proteins in 273 
various subcellular fractions and (b) for validation of protein level 274 
changes. Fractions (20 fig protein) were either pelleted (15 min 275 
at 10 OOOg) for mitochondria-enriched fractions or acetone 276 
precipitated prior to resuspension in reducing sample buffer 277 
(0.125 M Tris, p H 6.8, 20% [v/v] glycerol, 4% [v/v] SDS, 278 
0.004% [w/v] bromophenol blue, 10% [v/v] /?-mercapto- 279 
ethanol). Samples were electrophoresed using SDS-PAGE as 280 
described by Laemmli in a 12% (w/v) polyacrylamide resolving 281 
gel. Proteins separated by SDS-PAGE were transferred onto a 282 
nitrocellulose membrane by wet blotting. Blotting efficiency 283 
was checked by staining with copper phthalocyanine 3,4',4",4'"- 284 
tetrasulfonic acid tetrasodium salt in 12.5 m M HC1. Digital 285 
images were recorded, blots destained in 12.5 m M N a O H and 286 
membranes blocked by incubation in 3% (w/v) Marvel milk 287 
powder for 1 h prior to immunoprobing. Blocked membranes 288 
were incubated in primary antibody overnight at 4 °C with gentle 289 
shaking. For detection of markers following subcellular fraction, 290 
the primary antibodies used were as follows: mouse anti-cyto- 291 
chrome c antibody (1:500 (v/v) dilution; Santa Cruz Biotech- 292 
nology, Inc.), rabbit ant i -GAPDH antibody and rabbit anti-Lamin 293 
A / C antibody (1:1000 (v/v); New England Biolabs, U.K.) and 294 
rabbit ant i-LAMP2 antibody (1:500 (v/v); Abeam pic, U .K . ) . For 295 
validation purposes, the primary antibodies used were as follows: 296 
anti-rabbit anti-Hsp60 antibody (1:5000 (v/v) Alexis Biochem- 297 
icals, U K ) , rabbit anti-VDAC antibody (1:1000 (v/v); New 298 
England Biolabs, U.K. ) , goat anti-GOT2 antibody (C-21) 299 
(1:1000 (v/v); Santa Cruz Biotechnology, Inc.), mouse anti- 300 
Hsp70 clone BRM-22 (1:10 000 (v/v); Sigma-Aldrich, U K ) , 301 
goat anti-fumarase antibody (1:1000 (v/v); Abnova, Taiwan), 302 
mouse anti-ATP synthase a-subunit antibody and mouse anti- 303 
A T P synthase subunit d antibody (1:1000 (v/v), Mitosciences, 304 
Inc.). Unbound primary antibody was removed by shaking in 305 
TBS containing0.1% (v/v) Tween20 (TBS-tween).Membranes 306 
were then incubated for 2 h at room temperature in either goat 307 
anti-mouse, goat anti-rabbit ( D A K O Ltd., U.K.) or AffiniPure 308 
Bovine Anti-Goat ( H + L ) (Stratech Scientific, U.K.) immuno- 309 
globulins, all bound to horseradish peroxidase ( H R P ) . Blots were 310 
finally washed in TBS-tween and incubated with H R P substrates 311 
for revelation by enhanced chemilunescence (ECL) following 312 
the manufacturer's instructions (Pierce); chemiluminescence 313 
was detected using the Fujifilm LAS 3100 (P^aytek Scientific 314 
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10|JMMPTP 100 uM MPTP 1 mM MPTP 2 mM MPTP 
Figure 1. Effects of M P T P on mouse N2a neuroblastoma cell and morphology. Mouse N2a cells were differentiated for 16 h prior to treatment with 
different concentrations of M P T P (0—2 mM). (A and B) M P T P cytotoxicity was measured using a panel of assays including M T T reduction, trypan blue 
exclusion and A T P measurement, following (A) 24 h (MTT, n = 7; Trypan blue, n = 4; ATP, n = 6) or (B) 48 h (MTT, n = 7; Trypan blue, n = 1; ATP, n = 
3) M P T P treatments (0—2 mM). Results are expressed as mean % viability ± SEM. Statistical analysis was carried out using the paired t test with a two-
tail distribution. *All values p < 0.05 when compared to respective controls. (C) Digital images taken following 24 or 48 h treatment (using an inverted 
microscope fitted with phase contrast optics); scale bar represents 20 fim. 
3is Limited, Germany). Only bands which were nonsaturated were 
316 used for analysis. T o allow comparison between samples, band 
317 intensities were measured using A I D A software according to the 
318 manufacturer's instructions (Raytek). Band intensities were first 
319 corrected for background and then for protein loading using the 
320 corresponding copper stained lane. Each result was then ex-
321 pressed as % intensity ± S E M compared to corresponding 
322 control. 
323 2DE Analysis 
324 Typically, three gels derived from three mitochondria-en-
325 riched preparations were analyzed in each group (treatment 
versus control). Mitochondria-enriched fractions containing 20 
(for comparative analysis) or 80 fig of protein (for identification) 
were pelleted, resuspended in 125 fiL of sample isoelectrofocus-
ing (IEF) rehydration buffer (8 M urea, 4% [w/v] C H A P S , 2% 
[v/v] carrier ampholyte, 0.0002% [w/v] bromophenol blue, 
65 m M D T T ) and shaken for 2 h at room temperature. Samples 
were applied onto ReadyStrip IPG strips (pH 3 ~ 10, p H 5~8 or 
p H 7—10, 7 cm, Bio-Rad, U.K.) and actively rehydrated for 13 h 
and 40 min at 50 V followed by IEF (250 V for 15 min linear, 
4000 V for 2 h linear, 4000 V for 10 000 V / h rapid) using a 
P R O T E A N IEF cell (Bio-Rad, U .K . ) . After IEF, strips were 
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either stored at —80 °C or processed immediately. For equilibra-
tion, strips were transferred to 2% (w/v) D T T in equilibration 
buffer (6 M urea, 2% (w/v) SDS, 20% (v/v) glycerol, 50 m M Tris 
p H 8.8,) followed by 15 min in 2.5% (w/v) iodoacetamide in 
equilibration buffer. The proteins were further fractionated by 
SDS-PAGE (as described above). For comparative purposes, gels 
were stained using SyproRuby dye following the manufacturer's 
instructions (invitrogen, U .K . ) . Gels were then imaged using a 
Fujifilm FLA-5100 scanner (Raytek Scientific Limited, Germany) 
and images were analyzed using Samespots software (Progenesis, 
U .K. ) . Data were transferred to the PG240 section of the 
software. Spots were selected if peak height was over 750 and 
observed as up- or down-regulated if p < 0.1 using paired t test 
carried out by the software and differentially expressed to more 
than 20% from one group to another. For identification of 
protein spots, gels were silver stained (PlusOne Silver staining 
kit, G E Healthcare) using a mass spectrometry compatible 
protocol. For 2D-blot analysis, gels were directly processed to 
wet blotting as described earlier. 
Mass Spectrometry Analysis 
Selected spots were excised from the gel, dehydrated in 50 fiL 
of acetonitrile ( A C N ) / 2 5 m M N H 4 H C 0 3 (2:l) for 15 min 
while shaking, rehydrated in 50 fiL of 25 m M N H 4 H C 0 3 for 10 
min, and then sequentially dehydrated, rehydrated, and dehy-
drated. Gel pieces were then dried and 15 fiL of 12.5 ng/fiL 
sequencing grade trypsin (Promega, U.K.) was added. Gel spots 
were incubated at 37 °C for 4 h. Tryptic digests were then 
transferred to fresh tubes and 10 fiL of 4:1 A C N / L C — M S grade 
water (v/v) was added to the gel pieces and left for 15 min while 
shaking. The supernatant was combined with the previous digest 
and 5 fiL of 0.1% trifluoroacetic acid ( T F A ) was added to each 
tube. Finally, 1 fiL sample was plated on the M A L D I plate 
followed by 1 fiL of 10 mg a-cyano-4-hydroxycinnamic acid 
( C H C A ) matrix (LaserBio Laboratories, France)/mL in 50% (v/v) 
A C N / 0 . 1 % (v/v) T F A . Peptide mass fingerprints were gener-
ated using a M A L D I - T O F mass spectrometer (Axima mass 
spectrometer, Shimadzu, U .K . ) . Proteins were identified using 
the Mascot search engine (http://www.matrixscience.com); 
stating "mus musculus" species, carboxymethyl and oxidized 
methionine as variable modifications and 0.2 Da peptide toler-
ance. Positive identity was given by scores over 56 (comparing 
Swiss-Prot database) and their molecular mass and p i were 
compared to the position of the spot on the 2DE. 
Statistical Analysis 
Data were statistically analyzed by a paired t test using a two-
tailed distribution. 
• RESULTS 
MPTP Cytotoxicity in Differentiated Mouse N2a Neuroblas-
toma Cells 
Following 16 h differentiation, N2a cells were treated with 
different concentrations of M P T P for either 24 or 48 h. Cytotoxic 
effects of M P T P were determined using a range of assays 
(Figure l ) . Following 24 h exposure to M P T P , A T P levels 
dropped in a concentration dependent-manner; 10 fiM M P T P 
significantly decreased A T P levels by 25% and 2 m M M P T P 
reduced A T P by more than 80% (Figure 1A). Both trypan blue 
exclusion and M T T reduction assays showed that cell viability 
was significantly reduced following 24 h exposure to 2 m M 
M P T P but not at lower M P T P concentrations (Figure 1A). 
Total Nuclear Cyto Mito 
Mitochondria 
Cytoplasm 
Nucleus 
Lysosomes 
Cytc 
GAPDH 
Lamin A/C 
LAMP2 
Markers 
Location 
Mitochondria 
Protein 
SDH1 
Cytc2 
Fractions 
Nucleus cytoplasm mitochondria 
2.38 ±0.20* 0.00 ±0.00* 4.5 ±1.24* 
1.91 ±0.95 0.52 ±0.13* 13.34 ±4.59* 
Cytoplasm 
Nucleus 
LDH1 
GAPDH2 
Lamin2 
Lysosome LAMP22 
Endoplasmic NADPH-cyt 
reticulum c reductase1 
0.92 ±0.60 0.79 ±0.53 0.12 ±0.06 
0.25 ±0.20* 0.9 ±0.33 0.15 ±0.06* 
27.51± 
10.18* 0.69 ±0.38 0.39 ±0.08* 
0.45 ±0.20 4.44 ±2.30* 2.31 ± 2.24 
0.48 ±0.20 1.12 ±0.08 0.25 ±0.12* 
Figure 2. Assessment of purity of various subcellular fractions using 
marker proteins. Mouse N2a cells were differentiated for 16 h prior to 
homogenization followed by differential centrifugation. The presence of 
a variety of markers was analyzed by Western blotting and enzyme 
activity assays. (A) Representative Western blots (20 fig loading in each 
well) showing the presence of a series of markers in each fraction (total 
extract, nuclear, cytoplasmic, mitochondrial). (B) Table of quantified 
results from activity assays and Western blots using Ada software . 
Specific activity of each enzyme measured was calculated relative to total 
extract (given a value of l ) ± SEM (n > 4). *All values p < 0.05 when 
compared to total extract using a paired r test with a two-tail distribu-
tion. Intensity of bands in each fraction was measured and quantified 
relative to total extracts (given a value of l ) ± SEM (n > 13). Cyt c, 
cytochrome c; Cyto, cytoplasmic; E R endoplasmic reticulum; GAPDH, 
glyceraldehyde 3-phosphate dehydrogenase; LAMP2, lysosomal-asso-
ciated membrane protein 2; L D H , lactate dehydrogenase; Mito, mito-
chondrial; NADPH-cyt c reductase, nicotinamide adenine dinucleotide 
phosphate-cytochrome c reductase; SDH, succinate dehydrogenase. 
By 48 h, 10 fiM M P T P reduced cell viability as measured by 
M T T and trypan blue (Figure IB). Following 24 h treatment, cell 
morphology indicated that cell death occurred at a concentration 
of 2 m M M P T P , represented by a reduction in cell volume, a 
spherical cell shape and a loss of membrane integrity (Figure 1C). 
Nevertheless, shortening of axon-like processes was apparent with 
M P T P concentrations as low as 10 fiM M P T P , exacerbated as 
M P T P concentration was increased. Following 48 h exposure, 10 
fiM M P T P resulted in a few rounded dead cells; however, cell death 
was more evident with 100 fiM and higher concentrations of M P T P . 
T o conclude, cell morphology and A T P levels were affected at 
lower M P T P concentrations than apparent cell death measured 
using trypan blue exclusion and M T T reduction. A concentration 
affecting morphology/ATP but not M T T reduction/trypan blue 
exclusion was defined as subcytotoxic and was chosen to observe 
changes occurring in the mitochondrial proteome prior to cell 
death. Consequently further analyses were carried out using 
1 m M M P T P for 24 h. 
Purity of Mitochondria-Enriched Fractions 
The mitochondrial markers cytochrome c and S D H were 
highly enriched (4.5- and 13-fold, respectively) in the mitochon-
drial pellet, while present at low levels in the nuclear pellet and 
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kDa 
116.2 
Control 1 mM MPTP 
Figure 3. Effects of subcytotoxic concentrations of M P T P on the N2a mitochondrial proteome. Mouse N2a cells were differentiated for 16 h prior to 
treatment with 1 m M M P T P for 24 h. Mitochondrial pellets were isolated and fractionated (50 fig) by2DE using pH3—10 andpH5—8 gradient strips, 
and proteins visualized using SyproRuby. Gel images were compared using Samespots software. Circled spots represent spots that changed in density (p 
< O.l) between 1 m M M P T P and control samples following a student paired t test. Alist of identified proteins affected by M P T P treatment is provided in 
Table 1. 
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420 
421 
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424 
425 
426 
427 
428 
429 
430 
431 
432 
433 
434 
highly depleted in the cytoplasmic fraction (Figure 2). Cyto-
plasmic, nuclear and endoplasmic reticulum (ER) markers were 
minimal within the mitochondria-enriched fraction; however, 
the lysosomal marker L A M P 2 appeared to be enriched in the 
mitochondrial fraction compared to the total extract but this was 
not stastistically significant. The majority of the lysosomal 
marker was present in the cytoplasmic fraction (enriched 4.4-
fold compared to total extract; Figure 2). Overall, subcellular 
marker analysis showed that the mitochondrial fraction was 
composed mainly of mitochondrial proteins and contained a 
low level of the lysosomal protein marker. The cytoplasmic 
fraction also contained low levels of noncytoplasmic protein 
markers. Thus, both mitochondrial and cytoplasmic fractions 
were deemed to be suitable for further analyses. O n the other 
hand, the nuclear fraction contained significant levels of cyto-
plasmic and mitochondrial markers (Figure 2), probably indica-
tive of incomplete cellular disruption (at least 25% nonlysed cells 
as measured by microscopic analysis, data not shown), and was 435 
therefore not used for further analysis. The relative distribution 436 
of a particular marker was not affected by M P T P treatment (refer 437 
to Supplementary Data 4). 438 
Effects of Subcytotoxic MPTP Treatments on the Mitochon-
drial Proteome 
Mitochondrial fractions from cells treated with 1 m M M P T P 
for 24 h were analyzed using 2DE. Figure 3 shows 2 D E profiles 
for treated and control samples using either broad ( p H 3 ~ 10 
linear) or narrower ( p H 5~8) p H gradient strips. Using the 
broad range strips, approximately 350 spots were detected. U p to 
6 proteins showed changes in levels following M P T P treatment 
with p < 0.05 using the software's in-built paired t test. T o ensure 
detection of as many differentially expressed proteins as possible, 
spots showing a change with a probability p < 0.1 (n - 3), 
discriminated from spots with p < 0.05, were also selected for 
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Table 1. List of Identified Proteins Significantly Altered by M P T P Treatment" 
spot no. controlsc treatmentsc % change protein identification accession i gef kDa PJ localization 
12 
15 
16 
17 
19 
2 
3 
5 
6 
7 
13 
21 
9 
27 
1 
11 
521 ±41 
454 ±61 
1564 ±386 
302 ±44 
3040 ± 150 
1428 ± 148 
1123 ±70 
5559 ±916 
1077 ± 249 
2416 ±211 
386 ± 77 
1122 ±103 
802 ± 27 
3872 ±447 
584 ±67 
3954 ±454 
337 ±417 
761 ±91 
2095 ± 376 
389 ±37 
3863 ± 161 
1709 ± 136 
1438 ± 129 
6900 ± 628 
1589 ±179 
3758 ± 70 
829 ± 135 
1648 ± 104 
1194 ±38 
5530 ±614 
438 ± 24 
5123 ±766 
-35%' 
+68%+ 
+34%+ 
+29%* 
+27%+ 
+20%+ 
+28%+ 
+24%' 
+48%' 
+56%' 
+115%' 
+47%+ 
+49%* 
+43%' 
-25%+ 
+30%+ 
Chapi 
ERP29 
Hsc70 
STIP1 
T C P E 
Hsp60 
irone Family 
P57759 
P63017 
Q60864 
P80316 
P63038 
Metabolic Enzymes 
SCOT1 
F M H 
GOT2 
M D H 
M D H 
E C H M 
E N O A 
Oxidative 
ETFO 
ATPase-d 
Q9D0K2 
P97807 
P05202 
P08249 
P08249 
Q8BH95 
P17182 
Phosphorylation 
Q99LC5 
Q9DCX2 
Mitochondrial Membrane Proteins 
I M M T 
VDAC1 
Q8CAQ8 
Q60932 
185 
83 
79 
90 
113 
62 
103 
89 
177 
101 
83 
335 
65 
150 
210 
196 
49% 
27% 
20% 
22% 
27% 
14% 
43% 
22% 
44% 
43% 
48% 
75% 
17% 
85% 
34% 
81% 
29 
71 
63 
60 
61 
56 
54 
41 
36 
36 
31 
47 
35 
19 
84 
30 
5.90 
5.37 
6.40 
5.72 
5.91 
8.73 
9.12 
9.00 
8.93 
8.93 
8.76 
6.37 
8.62 
5.88 
6.18 
8.62 
ER 
Ubiquitous 
Ubiquitous 
Ubiquitous 
Matrix 
Matrix 
I M M 
Matrix 
Matrix 
Matrix 
Matrix 
Cyto-mb 
Matrix 
I M M 
I M M 
O M M 
a
 *Statistically significant changes p < 0.05 using a paired t test. Statistically significant changes p < 0.1 using a paired t test. A T P synthase-OL, ATP 
synthase OL-subunit isoform 1; A T P synthase-d, A T P synthase subunit-d; Cyto-mb, membrane protein on cytoplasmic side; E C H M , EnoylCoA 
hydratase mitochondrial; ENOA, OL-enolase; ERp29, endoplasmic reticulum resident protein 29; ETFOL, electron transfer flavoprotein subunit-OL; F M H : 
fumarase; GOT2, glutamate oxaloacetate transaminase 2; Hsp60:,60 kDa heat shock protein; Hsc70, heat shock cognate 71 kDa; I M M , inner 
mitochondrial membrane; Matrix, mitochondrial matrix; M D H , malate dehydrogenase; O M M , outer mitochondrial membrane; SCOT1, succinyl-
CoA:3-ketoacid-coenzyme A transferase 1, STIP1, stress-induced protein 1; TCPE, T-complex protein 1 subunit epsilon; VDAC1, Voltage-dependent-
anion channel 1. Spot numbers can be mapped back to show their positions in Figure 3. 'Average of normalized volumes (n = 3) ± SEM. Accession 
number from the Protein Knowledgebase UniProtKb: http://www.uniprot.org. 'Protein score greater than 54 are significant according to the Mascot 
database.' Coverage of all peptide sequences matched to the identified protein sequence. 
451 
452 
453 
454 
455 
456 
457 
458 
459 
460 
461 
462 
463 
464 
465 
466 
467 
468 
469 
470 
471 
472 
473 
474 
475 
identification and for validation analysis, leading to the identifica-
tion of at least 14 differentially expressed proteins following 
treatment. Most of these changes were in the basic area of the gel. 
Enriching the neutral p H area (pH 5—8) showed that more 
proteins were affected (13 spots) by the toxin treatment than 
observed using the broad p H gradient strips in the same area. 
Combining both analyses, 27 spots were either up- or down-
regulated following exposure to M P T P of which 16 were 
identified. Table 1 shows the list of identified proteins affected 
by subcytotoxic concentrations of M P T P , including proteins 
from the chaperone family, metabolic enzymes, subunits of 
oxidative phosphorylation and membrane proteins. Most of 
these proteins are either known to have distinct localizations in 
mitochondria, or to be ubiquitously distributed within a cell. 
Validation of Potential Markers of MPTP Subcytotoxicity 
T o confirm the changes observed, some of these proteins were 
further analyzed by probing Western blots with specific anti-
bodies. In addition to mitochondria-enriched fractions, the levels 
of these proteins were measured in unfractionated ('total') 
extracts and cytoplasmic fractions. The Western blotting data 
(top of each panel, Figure 4) shows that, except for Hsc70 
(localized ubiquitously in the cell), proteins were found in lower 
levels in the cytoplasmic fraction, in line with specific localization 
to mitochondria. More particularly, V D A C 1 and A T P synthase-d 
were not detected in the cytoplasmic fraction (Western blot 
images shown in Figure 4B,C). Western blot analysis indicated 
that all proteins whose levels in the mitochondrial proteome 
changed following M P T P treatment showed the same trend 
using Western blot analysis. Specifically, F M H , V D A C 1 , A T P 
synthase-d, G O T 2 , Hsp60 and Hsc70 were all significantly up-
regulated in mitochondria following treatment, validating the 
results from the 2 D E analysis (Figure 4 and Table 2). 
In general, the percentage changes were higher using the 
Western blot analysis than the 2 D E approach. Western blot 
analysis of the mitochondrial protein A T P synthase a-subunit, 
chosen as a control since 2DE indicated that its level did not 
significantly change following M P T P treatment, also revealed no 
change in its level (Table 2). 
Hsc70 levels increased in the mitochondria-enriched fraction 
but this increase was not detectable in total extracts due to the 
fact that there was no increase in the cytoplasmic fraction, where 
it was most prevalent (Figure 4D). 
Two-dimensional gel electrophoresis technology can separate 
isoforms of the same protein, whereas ID-Western blot analysis 
provides a measure of total protein levels within a single band. 
Therefore, further analysis focusing on isoforms of the same 
protein was carried out for the heat shock proteins and V D A C 1 
using 2D-Western blot analysis. Figure 5A (left panel) shows that 
two Hsc70 isoforms were detected using Western blotting. The 
main spot (spot 15') was identified as Hsc70 (refer to Supple-
mentary Data 1 and Figure 5A right panel) whose levels were not 
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Figure 4. Validation and quantification of identified changes in cellular fractions from mouse N2a neuroblastoma following treatment with subcytotoxic 
concentrations of M P T P . Mouse N2a cells were differentiated for 16 h prior to treatment with 1 m M M P T P and subcellular fractionation peformed. 
Western blotting analysis was performed on different fractions (total extract, cytoplasmic and mitochondrial). Blots were detected for the presence of 
(A) fumarase, (B) VDAC1, (C) A T P synthase d subunit, (D) GOT2, (E) Hsp60, and (F) HSC70. Densitometry of Western blots was quantified using 
Aida software, each band compared to total protein (20 fig equal loading/well). Data represented as % protein marker/total protein compared to 
controls (n > 4). Statistically significant changes p < 0.05 using a paired t test. A T P synthase-d, A T P synthase subunit d; F M H , fumarase; C, control 
sample; GOT2, glutamate oxaloacetate transaminase 2; Hsp60, 60 kDa heat shock protein; Hsc70, heat shock cognate 71 kDa; M , MPTP-treated 
sample; VDAC1, voltage-dependent-anion channel 1. 
found to be affected by M P T P treatment (Figure 3). In contrast, 
the smaller acidic spot (spot 15, Figure 5A) became more 
prominent following treatment with M P T P (Figure 3). 
U p to three Hsp60 isoforms were detected by Western 
blotting: the predominant spot, colocalizing with spot 19 from 
Figure 3 (also right panel Figure 5B), plus two smaller spots of 
same molecular weight (Figure 5B, left panel). Only the main 
central spot increased in levels following M P T P treatment. 
2D-blot analysis revealed a number of V D A C 1 spots; the main 
spot (spot l l ) was associated with three small relatively acidic 
spots and a number of isoforms (represented as a smear) with a 
more alkaline isoelectric point (Figure 5C, left panel). The main 
spot stained more intensely on 2D-blots of MPTP-treated cell 
extracts. 
• DISCUSSION si6 
Effects of Subcytotoxic Concentrations of MPTP on the 517 
Mitochondrial Proteome from Mouse N2a Neuroblastoma sis 
In the present study, treatment with up to 1 m M M P T P for 24 519 
h was considered subcytotoxic in differentiated mouse N2a cells; 520 
cell viability assessed using trypan blue exclusion and M T T 521 
reduction was not affected but morphological changes and 522 
reduced A T P levels were observed. Interestingly, even though 523 
A T P levels were reduced following treatment with low M P T P 524 
concentrations (as low as 10 fiM), cell death only significantly 525 
occurred when more than 50% A T P was depleted suggesting that 526 
a threshold A T P level (20—50% of controls in the present model, 527 
Figure 1A) might be required for maintaining the survival of the 528 
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Table 2. Comparison of Western Blot Data (ID-blot) with 
2DE Analysis" 
protein identification 
FMH 
VDAC1 
A T P synthase-d 
GOT2 
Hsp60 
Hsc70 
2DE 
+28%T 
+30%+ 
+43%+ 
+24%* 
+27%+ 
+68%+ 
ID-blot 
+ 108%* 
+228%* 
+324%* 
+59%* 
+20%* 
+60%* 
A T P synthase-a +17% +11% 
a
 Densitometry o f Western blots shown in Figure 4 was compared to 
2 D E analysis (data presented in Figure 3). A T P synthase-a was used as a 
control protein, exhibiting no changes in levels. *Statistically significant 
changes p < 0.05 using a paired t test. Statistically significant changesp < 
0.1 using a paired r test. A T P synthase-a, A T P synthase a-subunit 
isoform 1; ATPsynthase-d, A T P synthase subunit d; F M H , fumarase; 
G O T 2 , glutamate oxaloacetate transaminase 2; H S P 6 0 , 60 k D a heat 
shock protein; H S P A 8 , heat shock cognate 71 kDa; V D A C 1 , voltage-
dependent-anion channel 1. 
A. Hsc70 
2D-blot 
15~ 
2D-gel 
control 
1 mM 
MPTP 
+ - + 
B. Hsp60 
2D-blot 
19 
19 
2D-gel 
S>9 
^8* 
control 
1 mM 
MPTP 
VDAC1 
2D-blot 
^3 control 
1 mM 
MPTP 
Figure 5. Isoform detection o f heat shock proteins and V D A C 1 shown 
to be differentially expressed following M P T P treatment using 2D-blot. 
Mouse N 2 a cells were differentiated for 16 h prior to treatment with 
1 m M M P T P . Mi tochondr ia l pellets were isolated and fractionated (50 
^ g ) by 2 D E followed by transfer to nitrocellulose membranes and 
detected for Hsc70 (A) , Hsp60 (B) , and V D A C 1 ( C ) presence. Each 
2D-blot (representative experiment) is accompanied by the correspond-
ing area o f 2 D E from Figure 3. A l l circled spots were identified by 
peptide fingerprinting. Numbered spots correspond to those in Figure 3. 
Spots 15 and A , Hsc70; Spot 19, Hsp60; Spot 11, V D A C 1 . -, acidic end; 
+ , basic end. 
529 cells. In the present model, reduced A T P levels were probably a 
530 direct consequence of complex I inhibition. ' The subcyto-
531 toxic effects on neuronal morphology could be due to altered 
532 cytoskeletal protein arrangement as previously noted. Indeed, De 
533 Girolamo and colleagues showed that a reduction in axonal 
outgrowth was linked to hyperphosphorylation of neurofila- 534 
ments N F - H , leading to a change in the stability of the cytoske- 535 
leton. Similarly to the present study, this phenomenon occurred 536 
prior to cell death. 537 
T o focus on mitochondrial dysfunction, mitochondria were 538 
enriched from differentiated mouse N2a cells. The use of markers 539 
for each subcellular fraction showed that the resulting mitochon- 540 
drial preparation was highly enriched in mitochondrial proteins, 541 
contained low levels of lysosomal proteins and traces of cyto- 542 
plasmic and endoplasmic reticulum proteins (Figure 2). Only 543 
10% of the identified proteins from the mitochondrial proteome 544 
2DE profile were not specific to mitochondria (refer to Supple- 545 
mentary Data 2 for localization of each identified protein), 546 
including proteins normally found in the cytosol and endoplas- 547 
mic reticulum, confirming the subcellular marker data. The 548 
purity of the mitochondria-enriched fraction and 2 D E profile 549 
was comparable with the study of Scheffler and colleagues (3.7- 550 
fold mitochondrial enrichment, low contamination levels) and 551 
better than that observed in the study of Pennington and collea- 552 
gues. 553 
Proteomic analysis using the 2 D E approach showed that the 554 
levels of 27 proteins changed following M P T P treatment and 16 555 
of these proteins were identified. Because of a relatively low 556 
statistical power (p < 0.1 using paired t test; n - 3), validation of 557 
the approach was essential. The availability of well characterized 558 
commercial antibodies allowed further analysis of expression 559 
levels of six proteins using Western blot analysis; changes in 560 
expression o f these proteins were confirmed, validating the 2 D E data. S6i 
The differentially expressed proteins were from different 562 
cellular pathways. Dysregulation in protein folding was indicated 563 
by increased levels of some chaperone family proteins, such as the 564 
ubiquitous heat shock cognate 71 kDa (Hsc70) and stress- 565 
induced protein 1 (STIP l ) , the cytoplasmic T-complex pro- 566 
tein-1 £-subunit ( T C P E ) and the mitochondrial 60 kDa heat 567 
shock protein (Hsp60), and with decreased levels of endoplasmic 568 
reticulum resident protein 29 (ERP29) in the mitochondrial 569 
fraction. The levels of proteins involved in several metabolic 570 
pathways were increased following MPTP-treatment, including: 571 
M D H and F M H (Krebs cycle), G O T 2 (amino acid metabolism), 572 
E C H M and E T F a (fatty acid /5-oxidation), S C O T 1 (ketone 573 
body metabolism), enolase (glycolysis) and A T P synthase-d 574 
(oxidative phosphorylation). T w o membrane proteins were also 575 
affected with increased levels of V D A C 1 and decreased levels of 576 
mitofilin. The present study showed that many mitochondrial 577 
pathways could be affected by M P T P treatment prior to cell death. 578 
Changes in Metabolic Pathways 579 
While A T P levels were reduced by 50% following M P T P 580 
treatment, A T P synthase subunit d levels ( A T P synthase-d) ssi 
increased, whereas A T P synthase F l complex a-subunit ( A T P 582 
synthase-a) levels were unaffected. These different effects on the 583 
two subunits within complex V were not unexpected given that 584 
the subunits have different functions, with the a-subunit binding 585 
nucleotides and subunit-d participating in stabilizing the F 1 / F 0 586 
complex. Increased subunit-d could be a compensatory me- 587 
chanism in response to declining A T P levels. Indeed, these 588 
results agree with the observations of Basso and colleagues in 589 
human post-mortem samples of the substantia nigra, and thereby 590 
support the use of the N2a model for this type of analysis. 591 
As indicated earlier, the protein levels of several metabolic 592 
enzymes were up-regulated fo l lowing treatment w i t h subcytotoxic 593 
concentrations of M P T P . The role of the proteins in the various 594 
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Figure 6. Simplified schematic presentation of metabolic pathways involved in MPTP-induced toxicity. Enzyme proteins in orange bold were observe to 
increase following M P T P treatment in the present study (refer to Figure 3). Metabolic pathways are indicated in purple. E C H M , enoylCoA hydratase 
mitochondrial; ENOA, OL-enolase; ETFOL, electron transfer flavoprotein subunit-OL; F M H , fumarase; GOT2, glutamate oxaloacetate transaminase 2; 
M D H , malate dehydrogenase; S C O T l , succinyl-CoA:3-ketoacid-coenzyme A transferase. 
595 pathways and possible interactions between the proteins are sum-
F6 596 marized in Figure 6. A n increase in enolase suggests an activation of 
597 the glycolytic pathway, thought to be protective in MPTP-induced 
598 toxicity models via the production of more ATP. 6 " ' 6 1 Fatty acid 
599 oxidation may also be increased in our model, suggested by increased 
600 levels of E T F a and E C H M , again leading to more A T P production. 
601 One consequence of complex I inhibition is the inability to 
602 reoxidize N A D H via the electron transfer chain. It has been 
603 proposed that the reversal of the M D H step to produce malate 
604 may protect mouse N2a cells against M P T P toxicity, also allowing 
605 N A D H reoxidation. Therefore, it is possible that the increased 
606 levels of M D H reported in the present study reflect an attempt to 
607 reoxidize N A D H . Evidence of F M H involvement has not been 
608 observed in other P D studies but one can speculate that increased 
609 F M H levels may similarly serve the purpose of increasing the 
6io production of malate as a substrate for cytosolic energy production 
611 (Figure 6). The consequence of increased levels of G O T 2 is not 
612 known in the present model but it should be noted that a previous 
613 study of the effects of M P T P on monkeys showed that M D H and 
614 G O T 2 activities were increased. Glutamate oxaloacetate transami-
615 nase 2 (GOT2), also called mitochondrial aspartate aminotransfer-
616 ase, is linked to the Krebs cycle (Figure 6) in the mitochondrial 
617 matrix. Increased extracellular glutamate levels have previously 
618 been described in P D and following MPTP-induced toxicity. A 
619 role for glutamate excitotoxicity in cell death following M P T P -
620 induced toxicity has been observed in a mouse model and 
621 G O T 2 increased levels might be involved in the process linking 
622 metabolic dysregulation and glutamate excitotoxicity. 
A consequence of an inability to oxidize acetylCoA may also 
be evident since the levels of S C O T l , involved in ketone body 
formation, are increased. Ketone body formation has previously 
been described as a protective mechanism of cells in P D 
models. ' However, changes in levels of S C O T l have not 
previously been reported in relation to complex I inhibition. 
Chaperone Family Proteins 
The levels of four chaperones within the mitochondria were 
increased in response to M P T P treatment. This type of response 
has commonly been reported under oxidative stress, often linked 
to protein aggregation and degradation impairment, as ob-
served in P D models and MPTP-induced models. 8,11,70 In-
creased levels of Hsc70, an ubiquitous protein, were only 
evident in the mitochondria-enriched fraction where an acidic 
isoform of the protein was specifically affected. Changes in post-
translational modifications to Hsc70 have been previously ob-
served in a number of models including nitration, oxidation 
and phosphorylation. The exact cause of the shift in p i in the 
present study and the consequence on mitochondrial location 
and chaperone function require further study. Hsc70 is involved 
in folding proteins as they exit ribosomes and in delivering 
proteins for degradation by both the ubiquitin—proteasome 
system and the lysosomes. It was also observed to play a 
protective role in M P T P toxicity in a variety of models and 
is found in Lewy bodies. ' O f particular significance for the 
present study is the fact that Hsc70 also has a key role in the 
transport of specific proteins into mitochondria. As for most 
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650 molecular chaperones, Hsc70 interaction with its substrates is 
651 dependent on A T P binding and several co-chaperones. One of 
652 these co-chaperones is STIP1 (or Hop) , whose levels were also 
653 increased in the present model. 
654 T-complex protein 1 (TCP1 or C C T or T R i C ) and Hsp60 are 
655 two different chaperone complexes that form the chaperonin 
656 family (60 kDa heat shock protein complexes). Although they 
657 have similar chaperone functions, they differ in structure, where 
658 Hsp60 is composed of 14 identical subunits divided into two 
659 stacked rings and T C P 1 is composed of at least 8 subunits that 
660 are encoded by unique genes. It was originally thought that 
661 they had specific and distinct subcellular locations with T C P 1 in 
662 the cytosol and Hsp60 in the mitochondria. However, it has 
663 recently been shown that there is a functional Hsp60 pool in the 
664 cytoplasm too, and the main difference between the two 
665 complex chaperonins is due to substrate specificity. Mitochon-
666 drial Hsp60 plays an important role in the folding of mitochon-
667 drial proteins following their entry into the organelle. Hsp60 has 
668 previously been observed to be affected in a variety of neurode-
669 generative conditions and is up-regulated in a number of P D 
670 models. ' The presence of the particular T C P l - e subunit in 
671 the mitochondrial fraction and the significance of the change in 
672 levels following M P T P have yet to be investigated. 
673 Endoplasmic resident protein 29 (ERp29) can be found in the 
674 E R lumen where it is thought to have a role in protein unfolding, 
675 adding disulfide bonds to proteins, assisting protein transport 
676 and secretion of mature proteins. ' A decrease in ERp29 
677 protein levels in mitochondria following M P T P treatment was 
678 observed; whether this is due to a decrease in mitochondria—ER 
679 interactions or a decrease in total cellular ERp29 levels is not 
680 known. 
68i Mitofi l in 
682 Mitofilin is an I M M protein with a peptide tail in the 
683 intermembrane space. ' Mitofilin knockdown studies in hu-
684 man HeLa cells showed that it had a role in cristae structure that 
685 led to increased biogenesis of I M M with no cristae junctions, 
686 which was thought to up-regulate ion flux, increase ROS produc-
687 tion, increase mitochondrial potential and impair the process of 
688 oxidative phosphorylation, all of which have also been observed 
689 in MPTP-induced models. ' Recently, Weihofen and 
690 colleagues found that mitofilin was one of the proteins inter-
691 acting with P I N K 1 , a mitochondrial protein kinase known to be 
692 disrupted in P D , linking mitochondrial morphology alteration 
693 with P I N K 1 -mutation models. It has also previously been 
694 reported that dopamine-induced oxidative stress led to decreased 
695 mitofilin levels and covalently modified protein, further 
696 linking oxidative stress and mitofilin protein. The decreased 
697 levels of mitofilin observed in the present study may then reflect 
698 the oxidative stress induced by complex I inhibition. 
699 VDAC1 
700 V D A C l , a voltage-gated channel located in the outer mito-
701 chondrial membrane, was also up-regulated following M P T P 
702 treatment. Interestingly, V D A C l is involved in the regulation of 
703 cellular pathways that are affected in P D . First, it has a role 
704 in calcium, N A D H reoxidation and glutamate homeostasis 
705 through its function as a channel and having affinity for these 
706 molecules. ' It has also been found to play a role in cell death 
707 by interacting with apoptotic molecules ' and is a target of 
708 several signaling kinases. ' A l inkbe tweenVDAC and complex 
709 I inhibition was recently made by Xiong and colleagues where 
710 V D A C protein and m R N A levels were observed to be elevated 
following rotenone-induced toxicity in Human SH-SY5Y neuro- 711 
nal cells. The present study showed that another complex I 712 
inhibitor, M P T P , also modulated V D A C 1 protein levels, and that 713 
this occurred prior to neuronal death. It would therefore appear 714 
that V D A C l up-regulation is a potential early marker of M P T P - 715 
induced cell death. Moreover, Lessner and colleagues found 716 
that V D A C l levels were increased in striatal extracts in a 717 
6-OHDA-hemiparkinsonian rat model of P D while Perriquet 718 
and colleagues reported that V D A C l levels increased in the 719 
striatum and cortex of Parkin knockdown mice (used as a genetic 720 
model of P D ) . Finally, V D A C l has recently been reported to be 721 
necessary for PINKl/Parkin-directed autophagy of damaged 722 
mitochondria. Thus, changes in V D A C may have a wider 723 
significance than previously thought in P D . In the present study, 724 
up to four different spots with different isoelectric points were 725 
detected using 2D-blot analysis, showing that the protein can 726 
exhibit multiple post-translational modifications, which could 727 
influence V D A C l function following M P T P treatment. 728 
• CONCLUSIONS 729 
T h e present study showed that several cellular pathways were 730 
affected by MPTP-induced toxicity prior to cell death. This has 731 
provided a more specific molecular insight into the pathways that are 732 
initially affected following complex I impairment. Up-regulation of 733 
several chaperone proteins in M P T P treated cells was observed, 734 
suggesting a link between metabolic changes due to complex 1 735 
inhibition and protein folding. Similarly, extra-mitochondrial pro- 736 
teins, most of them known to be able to associate with mitochondria, 737 
were also affected following mitochondrial impairment showing that 738 
the insult was spreading to the rest of the cell. It is suggested here that 739 
V D A C 1, a multifunction outer mitochondrial membrane, could have 740 
a key role in signaling between mitochondria and the rest of the cell. 741 
It could also be considered as a subcytotoxic biomarker of imminent 742 
cell death and we propose that further study should be undertaken to 743 
establish the precise role of V D A C in PD-linked cell death. Since 744 
complex 1 dysfunction is a biochemical characteristic described in 745 
Parkinson's disease, we believe that our work provides newimportant 746 
information of relevance to this condition. 747 
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766 • ABBREVIATIONS 
767 2 D E , 2-dimensional-gel electrophoresis; A C N , acetonitrile; A T P 
768 synthase-a, A T P synthase a-subunit isoform 1; A T P synthase-d, 
769 A T P synthase subunit d; C H C A , a-cyano-4-hydroxycinnamic 
770 acid; Cyt c , cytochrome c; dbcAMP , dibutryl adenosine 3',5'-
771 cyclic monophosphate; D M E M , Dulbecco's Modified Eagle 
772 Medium; D T T , dithiothreitol; E B , extraction buffer; E C H M , 
773 enoylCoA hydratase mitochondrial; E C L , enhanced chemilumi-
774 nescence; E N O A , a-enolase; ERP29 , endoplasmic reticulum 
775 resident protein 29; E T C , electron transfer chain; E T F a , electron 
776 transfer flavoprotein subunit-a; F M H , fumarase; G A P D H , gly-
777 ceraldehyde-3-phosphate dehydrogenase; G O T 2 , glutamate ox-
778 aloacetate transaminase 2; H R P , horseradish peroxidase; Hsc70 , 
779 heat shock cognate 71 kDa; Hsp60 , 60 kDa heat shock protein; 
780 IEF , isoelectrofocusing; I M M , inner mitochondrial membrane; 
781 L A M P 2 , lysosomal-associated membrane protein 2; L C — M S , 
782 liquid chromatography—mass spectrometry; L D H , lactate dehy-
783 drogenase; M A L D I - T O F , matrix-assisted laser desorption/ioni-
784 zation—time-of-flight; M A O , monoamine oxidase; M D H , malate 
785 dehydrogenase; M P P + , 1 -methyl-4-phenylpyrimidium; M P T P , 
786 l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine;MTT , 3-(4,5-di-
787 methylthiazol-2-yl)-2;5-diphenyltetrazolium bromide; N A D P H , 
788 nicotinamide adenine dinucleotide phosphate; O M M , outer 
789 mitochondrial membrane; P D , Parkinson's disease; p i , isoelectric 
790 point; P F N K l , phosphatase and tensin homologue-induced puta-
791 tive kinase l ; S C O T l , succinyl-CoA:3-ketoacid-coenzyme A 
792 transferase 1; S D H , succinate dehydrogenase; SDS-PAGE , so-
793 dium dodecyl-sulfate-polyacrylamide gel electrophoresis; STIP1 , 
794 stress-induced protein 1; T E , total extract; T C P E , T-complex 
795 protein 1 subunit epsilon;VDAC , voltage-dependent-anion 
796 channel 
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